Why Prioritizing Quality Over Cost is Crucial in Biologics Manufacturing
When a biotech company begins manufacturing for clinical trials, it may receive low-cost offers from contract development and manufacturing organizations (CDMOs). Sponsors should be cautious of these proposals and prioritize quality over cost. In biologics manufacturing, quality is essential for business and patient safety. Cutting corners on quality is not an option. Experienced professionals understand that failing to invest in quality upfront leads to higher costs later. As the saying goes, “The bitterness of poor quality remains long after the sweetness of low price is forgotten."
Why Prioritizing Quality Over Cost is Crucial in Biologics Manufacturing